Researchers at William Sansum Diabetes Center in Santa Barbara (United States) have discovered that the African -American population has very low presence in clinical trials performed with new diabetes treatments, despite the fact that the incidence of this disease is almost twice asof the white population.
The finding, published in the magazineantiglemic were subjected to cardiovascular safety tests, which could strain depending on the breed or ethnicity of patients.
In five of them, as they saw, African Americans represented less than 5 percent of all participants."They are underrepresented in clinical trials with new therapies and devices," said David Kerr, one of the study authors.
In fact, this expert admits that the low presence of a subgroup of affected could favor that they were exposed to "therapies that may not work or be harmful," according to Kerr.
This expert recalls that the diabetes rate among the African -American population is around 13 percent, compared to 7.6 percent of the white population.Also, mortality rates due to cardiovascular diseases are also disproportionately higher among the black population.
When it comes to the effectiveness and safety of medicines, the breed does not necessarily condition the response to a treatment but does not guarantee that the results will be similar.
However, most cardiovascular studies in recent decades have focused on white heterosexual men, Andrew Krumerman, from the Albert Einstein Medical College and the Montefiore Medical Center in New York.
"The current study confirms that African -American subjects are poorly represented in the great cardiovascular clinical trials," added this expert, which did not participate in the study.
However, this finding seems to transcend beyond diabetes since, for example, there are studies that have discovered that two types of drugs for blood pressure do not work just as well in black patients as another type, at the timeThat it has been observed that another for heart failure works especially well in black patients but not in whites.
"For some time we have known that high -risk minority populations have been infrarrepreneed in clinical trials," according to Daniel Lackland, a researcher at the Medical University of South Carolina who did not participate in the study and that extends this fact to the trialsclinicians with some antitumor drugs.
